Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 30, 2009 Brian Orelli	Good Luck in 2010, Zimmer Medical device maker Zimmer met analysts expectations in the fourth quarter, but investors weren't impressed with the company's guidance.
The Motley Fool January 31, 2006 Stephen D. Simpson	Zimmer Muddles Through So long as the pressures in the orthopedic sector prove less than originally feared, investors could still make money here.
The Motley Fool July 28, 2010 Brian Orelli	Amplifying the Risk-Reward Ratio Amplify, Medtronic's latest, gets a mixed reaction at FDA advisory panel meeting.
The Motley Fool July 28, 2005 Stephen D. Simpson	Zimmer at a Simmer Strong demand for reconstructive products keeps this orthopedics company limber. Zimmer's 30-plus trailing price-to-earnings ratio still looks high, but it is in line with this industry's current multiples.
The Motley Fool July 23, 2010 Jordan DiPietro	Better Health Care Buy: Stryker or Zimmer Holdings? Which stock is a better purchase to consider?
The Motley Fool July 17, 2008 Brian Orelli	Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release
The Motley Fool April 27, 2007 Ryan Fuhrmann	Hip Results at Zimmer Holdings The orthopedic-implant and surgical-product maker is impressing investors, and it may just be warming up.
The Motley Fool February 24, 2009 Brian Orelli	Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success.
The Motley Fool January 22, 2009 Brian Orelli	Abbott Labs Thumbs Nose at Recession On a GAAP basis, Abbott Labs fourth-quarter earnings per share were up a whopping 27%, and even better, the double-digit increases don't look like they're going to stop anytime soon.
The Motley Fool August 27, 2010 Brian Orelli	A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much.
The Motley Fool October 18, 2007 Billy Fisher	An Empire Strykes Back Stryker reports a quarter of double-digit growth in revenue and earnings. Investors, take note.
The Motley Fool October 17, 2008 Brian Orelli	Shareholders Slap Stryker A little earnings miss sends the medical technology company down more than necessary.
The Motley Fool October 20, 2011 Brian Orelli	Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other.
The Motley Fool April 29, 2011 David Williamson	Johnson & Johnson's Traumatic Purchase Johnson & Johnson agrees to purchase trauma and spine specialist Synthes.
The Motley Fool October 14, 2009 Brian Orelli	Consistency Makes This Stock a Winner Abbott turns in a solid quarter, but it needs to keep branching out.
The Motley Fool November 8, 2011 Brian Wilson	2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues.
The Motley Fool July 26, 2007 Ryan Fuhrmann	Zimmer Simmers The maker of hip and knee replacements gets a leg up on the market. Investors, take note.
The Motley Fool April 27, 2006 Stephen D. Simpson	Guidance Brings Zimmer to Its Knees Sales were a little light this quarter, and the company will have to hustle to meet full-year projections. Investors, tread carefully and only buy when there is a fitting margin of safety here.
The Motley Fool October 25, 2007 Billy Fisher	Plenty of Strength in Zimmer Orthopedic manufacturer Zimmer Holdings reports a solid third quarter, but lowers its forecast for Q4.
The Motley Fool June 4, 2010 Jim Mueller	The Changing Face of Abbott Abbott Labs' shift in revenue sources has been a boon over the last five years.
The Motley Fool April 28, 2004 Glen Trematore	Zimmer Makes a Family Proud Zimmer Holdings looks strong when compared with other orthopedic/medical device makers.
The Motley Fool December 18, 2008 Brian Orelli	A Diagnostic Tongue Twister Back-scratch fever between Abbott and Isis.
The Motley Fool February 24, 2011 Brian Orelli	Abbott: 1, Johnson & Johnson: 0 -- For Now Abbott Labs got a ruling overturned yesterday that would have cost the company $1.8 billion, yet investors let shares slip down 1%.
The Motley Fool January 27, 2010 Brian Orelli	Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that.
The Motley Fool April 26, 2005 Stephen D. Simpson	Growth Is Knee-High Zimmer turns in another fine quarter, with strength in knee implants leading the way.
The Motley Fool January 30, 2007 Ryan Fuhrmann	Zimmer Implants a New High Investors, the orthopedic designer, developer, and manufacturer isn't cheap, but stellar companies rarely are.
The Motley Fool August 20, 2008 Brian Orelli	Medtronic Muddles Through The medical device maker manages double-digit growth in a tough market.
The Motley Fool June 26, 2009 Brian Orelli	Change at Top Looks Good for Bottom Line Investors welcome Boston Scientific's new boss.
The Motley Fool October 15, 2008 Brian Orelli	Abbott's Stents Aren't (That) Important Abbott's shareholders shouldn't be too focused on drug-eluting stents.
The Motley Fool February 24, 2010 Brian Orelli	Medtronic Needs to Regrow a Spine Everything else looks fairly good, but the problem I see involves the slight decline in Medtronic's second-largest segment, spinal products.
The Motley Fool July 19, 2011 Brian Orelli	J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile.
The Motley Fool July 7, 2008 Brian Orelli	And Then There Were 4 The number of drug-eluting stent players in the U.S. doubles with the addition of Medtronic's Endeavor and Abbott Labs' Xience V.
The Motley Fool May 21, 2008 Brian Orelli	Medtronic's Endeavors Look Good The medical device maker's new drug-eluting stent helps push up revenue.
The Motley Fool July 27, 2006 Stephen D. Simpson	Zimmer Provides Quarterly Information, and More In addition to its quarterly review, the orthopedic company gave some insight into the government probe. Investors, take note.
BusinessWeek January 29, 2007 Michael Arndt	Abbot Labs: Diagnosis: Shrewd Moves Abbott Laboratories has announced that it is selling about two-thirds of its $4 billion diagnostics business to buy more medical products outfits to help boost overall sales and profits by at least 10% a year into the next decade.
The Motley Fool February 1, 2005 Stephen D. Simpson	Zimmer Shoots From the Hip Pure-play orthopedic company delivers the goods, but at what cost? Zimmer carries a price tag that would make a value investor's bones ache.
The Motley Fool April 17, 2008 Brian Orelli	Abbott's Not Ailing Abbott produces double-digit growth; investors yawn.
The Motley Fool November 18, 2008 Brian Orelli	No Buffer for Medtronic Even though sales grew for the quarter, investors weren't happy.
The Motley Fool August 18, 2008 Brian Orelli	Foolish Forecast: Taking Medtronic to Heart In advance of earnings analysts expect Medtronic, with another medical device approval, to boost revenues 17%.
The Motley Fool January 12, 2009 Brian Orelli	Abbott Eyes New Growth Abbott announces it's buying eye-care specialist Advanced Medical Optics for $22 per share -- nearly 150% higher than Friday's close on the stock.
The Motley Fool August 4, 2010 Matt Koppenheffer	How Much Is Abbott Labs Worth? Is Abbott Labs' stock on sale?
The Motley Fool October 21, 2010 Brian Orelli	Abbott Just Can't Get Any Love Despite meeting or beating analysts' earnings for a streak that stretches balk half a decade, Abbott Labs hasn't been able to get much love from investors.
The Motley Fool April 15, 2009 Brian Orelli	Abbott's on Sale Abbott isn't firing on all cylinders the way it was last year, but things still look fine, and the stock is selling at a discount right now.
The Motley Fool January 17, 2006 Stephen D. Simpson	High-Stakes Medical Device Chicken Boston Scientific has upped the ante again. Are they bluffing? Their latest offer is $80 a share -- $42 in cash and $38 in stock. Let's hope the board knows what it is doing, because it is staking the company on this.
The Motley Fool February 17, 2005 Stephen D. Simpson	Is Medtronic's Heartbeat Slowing? Will gradually decelerating growth lead to a multiple contraction on the medical device maker's stock?
The Motley Fool April 8, 2005 Stephen D. Simpson	Abbott Hopes to Maxx Out Abbott announced FDA approval to begin a pivotal trial for its drug-eluting stent. Will this be too little too late for shareholders, or a true dark horse?
The Motley Fool August 24, 2010 Brian Orelli	Disaster in Medical-Device Land Industry bellwether Medtronic is forecasting a nasty storm.
The Motley Fool June 4, 2010 Brian Orelli	Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other.
The Motley Fool August 29, 2008 Brian Orelli	Stent Makers Getting Desperate Johnson & Johnson, the first company to bring a drug-eluting stent to the U.S. market, seems like it might be getting a little desperate, as competition increases.
The Motley Fool May 26, 2005 Stephen D. Simpson	A Second Opinion on Medtronic Medtronic is a growth stalwart, but does valuation properly account for the challenges?